NDC product
PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND
NDC 0517-4300 · American Regent, Inc.
Key facts
| Product NDC | 0517-4300 |
|---|---|
| Proprietary name | PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND |
| Nonproprietary name | Paclitaxel |
| Substances | PACLITAXEL |
| Dosage form | INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION |
| Route | INTRAVENOUS |
| Labeler | American Regent, Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | NDA |
| Application number | NDA211875 |
| Pharmacologic classes | Microtubule Inhibition [PE], Microtubule Inhibitor [EPC] |
| Marketing start | May 2, 2023 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: